Mažų ląstelių – didelė vertė Home - Clinical potential of cord blood-derived multipotent stem cells in Type 1 diabetes therapy
 
Back
 

Clinical potential of cord blood-derived multipotent stem cells in Type 1 diabetes therapy 2012-02-10

Type 1 diabetes is caused by the body’s own immune system attacking its pancreatic islet β cells and requires daily injections of insulin to regulate the patient’s blood glucose levels. A new method described uses stem cells from cord blood to re-educate a diabetic’s own T cells and consequently restart pancreatic function reducing the need for insulin.

 
Stem Cell Educator therapy slowly passes lymphocytes separated from a patient’s blood over immobilized cord blood stem cells (CBSC) from healthy donors. After three hours in the device the re-educated lymphocytes are returned to the patient. The progress of the patients was checked at 4, 12, 24 and 40 weeks after therapy.
 
In an open-label, phase1/phase 2 study, 15 patients with type I diabetes received one treatment with the re-educated T cells. Median age was 29 years (range, 15 to 41), and median diabetic history was 8 years (range, 1 to 21). This therapy reversed autoimmunity and promoted regeneration of islet ß cells, wich resulted decreasion of the median daily dose of of insulin.  A single treatment produces lasting improvement in metabolic control. 
 
Scientist now think, that successful immune modulation by umbilical cord stem cells and the resulting clinical improvement in patient status may have important implications for other autoimmune and inflammation-related diseases.
 
Research description here 
 
About Type I diabetes here